Blog

DNA-based vaccines represent a simple, safe and promising strategy for harnessing the immune system to fight infectious diseases as well as various forms of cancer.

STONY BROOK, N.Y. and TORONTO, CANADA – March 14, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, and Spindle Biotech Inc. (“Spindle Biotech”), a company focused on the development of a novel, high yield, and low-cost RNA production systems, today announced that the two companies have executed […]

Cancer crusade: Stony Brook-based Applied DNA Sciences and Italian biopharma EvviVax are one step closer to a bona fide DNA-based cancer vaccine. FEBRUARY 17, 2022 By GREGORY ZELLER // New vaccines produced in part by a progressive Long Island biotech could significantly increase the efficacy of existing cancer treatments. The potential breakthrough – detailed this month in […]

– First Published Study Demonstrates LinearDNA Pan-Cancer and Colon Cancer Neoantigen – – Targeted Vaccines Elicit a Therapeutic Immune Response in Animal Cancer Models – – LinearDNA Vaccines Elicits Strong Antigen-specific Immune Responses and Significantly Reduces Tumor Growth – – Manuscript Summarizing Findings Posted to Preprint Server and Submitted for Peer-Reviewed Publication – STONY BROOK, […]

STONY BROOK, N.Y. – November 15, 2021 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, and its majority-owned subsidiary LineaRx, Inc., a manufacturer of LinearDNA™ via PCR for nucleic acid therapeutics and diagnostics, today announced the receipt of repeat orders from […]

Preclinical Study Details Application of LinearDNA Suitable for the Cost-Effective Production of CAR T Cells Results Demonstrate that CAR19 T-cells Manufactured with LinearDNA Have Similar Efficacy to CAR19 T-cells Manufactured with Plasmid DNA STONY BROOK, N.Y. – November 9, 2021 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction […]

STONY BROOK, N.Y. – November 9, 2021 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, announced the publication of a study in Molecular Therapy: Methods and Clinical Development on a methodology for the manufacture of novel types of […]

STONY BROOK, N.Y. and ROME, ITALY – June 7, 2021 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its program development partner, Evvivax, S.R.L. (“Evvivax”), today announced results from an in vitro neutralization study of sera from the trial cohort comprised of 11 domestic felines vaccinated […]

Applied DNA and Evvivax Announce that LinearDNA™ COVID-19 Vaccine Candidate Booster Yields 5-Fold Average Increase in Neutralizing Antibody Titers in Domestic Felines Manufactured by an enzyme and without bacteria, LinearDNA vaccine candidate is virus-free, plasmid-free DNA Vaccine candidate induced neutralizing titers in 100% of trial cohort Based on positive study results, companies plan to accelerate […]

COVID Feline Vaccine Candidate Previously Demonstrated Antibodies and T-cell Response in Mouse ModelsClinical Trial to Serve as Initial Validation of LinearDNA Platform in Large Mammals with Potential Advantages in Manufacturing, Storage, and Distribution over Other Vaccines STONY BROOK, N.Y. & ROME. March 2, 2021. Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase […]